Ascend's Innovation Enhances AAV Production Efficiency

Ascend Advanced Therapies has revealed new data showcasing enhancers that significantly boost adeno-associated virus (AAV) yields. The two proprietary enhancers, developed through collaborative research, have demonstrated an up to threefold increase in AAV production without compromising quality. These enhancers have been tested in varying scales, including HEK293 cells and different bioreactor systems.

Results show that Enhancer 1 can produce up to three times more AAV using Ascend's EpyQ® system, while Enhancer 2 achieves up to a 2.4-fold increase. Both enhancers maintain quality parameters, addressing a major challenge in gene therapy manufacturing. Ascend plans to offer the technology under license, potentially doubling patient reach per vector batch and lowering production costs.

Ascend's move to integrate these enhancers into their manufacturing workflows aims at providing cost-effective, high-quality AAV vectors. This development reinforces their position as a leader in efficient, high-quality gene therapy manufacturing.